Results 81 to 90 of about 5,430 (178)

Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study

Drugs in Context, 2020
Background: The once-daily oral combination of daclatasvir (DCV) and sofosbuvir (SOF), with or without ribavirin (RBV), is effective and well tolerated in patients with hepatitis C virus (HCV).
Rodolfo Sacco, Vincenzo Messina, Umberto Vespasiani Gentilucci, Luigi Elio Adinolfi, Antonio Ascione, Giorgio Barbarini, Angelo Barlattani, Giuseppe Cariti , Raffaele Cozzolongo, Basilio Fimiani, Ruggiero Francavilla, Caterina Furlan, Giovanni Garrucciu, Vincenzo Iovinella, Luca Rinaldi, Massimo Marignani, Paola Begini, Valeria Pace Palitti, Adriano M Pellicelli, Gaetano Scifo, Antonio Facciorusso, Luca Giacomelli, Aashni Shah, Gaetano Bertino, Serena Perazzo, Giampaolo Bresci, Antonio Izzi   +26 more
doaj   +1 more source

Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience

Infection and Drug Resistance, 2021
Qiao Tang, Li Wei, Xiaoqing Liu, Peng Hu Department of Infectious Diseases, Institute for Viral Hepatitis, The Key Laboratory of Molecular Biology for Infectious Diseases, Chinese Ministry of Education, The Second Affiliated Hospital of Chongqing Medical
Tang Q, Wei L, Liu X, Hu P
doaj  

Daclatasvir [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity.

PLoS Pathogens, 2014
Widely used chemical genetic screens have greatly facilitated the identification of many antiviral agents. However, the regions of interaction and inhibitory mechanisms of many therapeutic candidates have yet to be elucidated.
Hangfei Qi, C Anders Olson, Nicholas C Wu, Ruian Ke, Claude Loverdo, Virginia Chu, Shawna Truong, Roland Remenyi, Zugen Chen, Yushen Du, Sheng-Yao Su, Laith Q Al-Mawsawi, Ting-Ting Wu, Shu-Hua Chen, Chung-Yen Lin, Weidong Zhong, James O Lloyd-Smith, Ren Sun   +17 more
doaj   +1 more source

RAS in NS3 and NS5A regions after failure of daclatasvir/asenaprevir combination therapy.

, 2016
RAS in NS3 and NS5A regions after failure of daclatasvir/asenaprevir combination therapy.
Miyako Murakawa (3239484), Takehiko Abe (3239505), Jun Itakura (554845), Shinya Sakita (3239508), Yasushi Ide (3239511), Masayuki Kurosaki (156560), Kouji Joko (3239496), Takashi Satou (3239469), Chikara Ogawa (3239478), Namiki Izumi (156627), Keiji Tsuji (3239502), Haruhiko Kobashi (3239490), Nobuyuki Enomoto (92837), Syotaro Tsuruta (3239475), Akeri Mitsuda (3239472), Yukio Osaki (170808), Kouichi Takaguchi (3239481), Hiroaki Okushin (3239499), Takashi Tamada (204139), Hiroyuki Hisai (3239493), Chitomi Hasebe (3239487), Hitoshi Yagisawa (147721), Yasuhiro Asahina (156563)   +22 more
core   +1 more source

METHOD DEVELOPMENT AND VALIDATION OF ULTRAVIOLET-VISIBLE SPECTROSCOPIC METHOD FOR THE ESTIMATION OF HEPATITIS-C DRUGS - DACLATASVIR AND SOFOSBUVIR IN ACTIVE PHARMACEUTICAL INGREDIENT FORM

, 2016
Objective: The objective of the present work is to develop a simple, efficient, and reproducible spectrophotometric method for the quantitativeestimation of hepatitis-C drugs - Daclatasvir and Sofosbuvir in its active pharmaceutical ingredient (API) form.
Sailaja Bbv, V Ashok Chakravarthy, Praveen Kumar A   +2 more
core   +2 more sources

Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study

Cogent Medicine, 2020
Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin, including patient-reported outcomes, in routine practice in three European countries: the CMPASS-EU cohort study. Objectives: To identify patient characteristics associated with routine
Stefan Bourgeois, Karel van Erpecum, Jean Delwaide, Uwe Naumann, Stefan Christensen, Christophe Moreno, Anita Pathil, Emile Schippers, Nancy van Emmerik, Benoit Caritey, Conrad Fischer, Florence Mercier, Joerg Petersen   +12 more
doaj   +1 more source

STABILITY INDICATING HPLC METHOD DEVELOPMENT AND VALIDATION FOR DETERMINATION OF DACLATASVIR IN PURE AND TABLETS DOSAGE FORMS

, 2017
A sensitive, simple, selective and accurate HPLC method was developed and validated for analysis of antiviral drug Daclatasvir (BMS-790052, DCV) in pure form and in tablet dosage form in the presence of its degradation products.
Hanaa Saleh, Gamal H. Ragab, Mohammed A. Othman
core   +1 more source

Avances en hepatitis C

Revista del Hospital Italiano de Buenos Aires
La hepatitis C es la principal causa de hepatitis crónica, cirrosis y cáncer de hígado, así como la indicación más común de trasplante hepático en la Argentina y muchos otros países.
Ezequiel Mauro, Sebastián Marciano, Omar Galdame, Adrián Gadano   +3 more
doaj  

Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection

, 2016
International audienceBACKGROUND & AIMS:We evaluated the combination of daclatasvir (pan-genotypic NS5A inhibitor) and simeprevir (NS3/4A protease inhibitor), with or without ribavirin, in hepatitis C virus genotype 1-infected patients.METHODS:This phase
Buti, Maria, Ouwerkerk-Mahadevan, Sivi, Cheung, Kin, Bronowicki, Jean-Pierre, Loustaud-Ratti, Veronique, Beumont-Mauviel, Maria, Makara, Mihaly, Mcphee, Fiona, Hughes, Eric A., Pruitt, Ronald, Al-Assi, M. Tarek, Noviello, Stephanie, Gea, Francisco, Thabut, Dominique, Olveira, Antonio, Gadano, Adrian, Petersen, Joerg, Bifano, Marc, Bourliere, Marc, Picchio, Gaston, Boparai, Navdeep, Pol, Stanislas, Hezode, Christophe, Banyai, Tivadar, Zeuzem, Stefan   +24 more
core   +1 more source